2. It is currently estimated that there are 25,000–40,000 different genes in
the human genome, viewed from the perspective of disease
mechanisms, as disease may result
when any one of these proteins contains
mutations or other abnormalities, so it
gives a tremendous opportunity for
Protein therapeutics to alleviate
these disease.
What is Protein therapeutics?
3. The Evolution of Protein Therapeutics : A Timeline
1953 First accurate model of DNA suggested
1982 Human insulin, created using recombinant DNA technology
1986 Interferon alfa and muromonab-CD3 approved
1997 First whole chimeric antibody, rituximab, and first humanized
antibody, daclizumab, approved
1993 CBER's Office of Therapeutics Research and Review (OTRR) formed
2002 Market for biotechnology products represents approximately $30
billion of $400 billion in yearly worldwide pharmaceutical sales
2006 An inhaled form of insulin (Exubera) approved, expanding protein
products into a new dosage form.
12. Futher work
Complete suppression of plasma HIV-1 RNA should be the goal in all
patients with HIV given the availability of new drugs
Maximize virus suppression while minimizing drug toxicity
For those who do not tolerate new agents, goal should be to maintain CD4
count as high as possible
Second line therapy should be chosen on the basis of resistance testing,
treatment history, tolerability
13. Reference
Benjamin Leader, Quentin J. Baca and David E. Golan; Protein therapeutics:
asummary and pharmacological classification. Nature review, volume 7,
January2008
Bange, J; Zwick E, Ullrich A. (2001). "Molecular targets for breast cancer
therapy andprevention". Nature Medicine 7 (5): 54552
Dipak S. P., Matthew P. K., Sathy V. B., “DELIVERY OF
THERAPEUTICPROTEINS”, J Pharm Sci. 2010 June; 99(6): 2557– 2575
WEB SOURCES:
http://www.marketresearch.com/RNCOS-v3175/Global-Protein-
Therapeutics-6430009/
http://www.pharmaphorum.com/2011/10/11/global-protein-therapeutics-
market-beefing-up-towards-futuristic-growth/
